<DOC>
	<DOCNO>NCT00064142</DOCNO>
	<brief_summary>This phase II trial study well halofuginone hydrobromide work treat patient human immunodeficiency virus ( HIV ) -related Kaposi 's sarcoma . Halofuginone hydrobromide ointment may stop growth Kaposi 's sarcoma stopping blood flow tumor .</brief_summary>
	<brief_title>Halofuginone Hydrobromide Treating Patients With HIV-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine tumor response rate acquire immune deficiency syndrome ( AIDS ) -related Kaposi 's sarcoma topical halofuginone ( halofuginone hydrobromide ) versus vehicle control . II . To evaluate safety tolerability topical halofuginone vehicle patient AIDS-related Kaposi 's sarcoma . SECONDARY OBJECTIVES : I . To determine ability topical halofuginone inhibit expression matrix metallopeptidase 2 ( MMP-2 ) Collagen type I AIDS-related Kaposi 's sarcoma . II . To explore relationship baseline cluster differentiation ( CD ) 4 CD8 count , HIV viral load human herpesvirus 8 ( HHV-8 ) viral load response halofuginone . III . To characterize pharmacokinetics halofuginone . OUTLINE : Twelve treatable Kaposi 's sarcoma lesion select patient , 12 lesion randomize equally 1 2 treatment arm ( 6 lesion receive study treatment 6 lesion receive placebo ) ; patient serve his/her control . ARM I : Patients apply topical halofuginone hydrobromide ointment 6 lesion twice day 12 week . ARM II : Patients apply topical placebo ointment 6 lesion twice day 12 week . Patients stable respond disease either group treat lesion ( halofuginone hydrobromide ointment placebo ointment ) may receive open-label treatment topical halofuginone hydrobromide ointment 12 lesion additional 12 week absence disease progression unacceptable toxicity . Patients follow least 1 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Halofuginone</mesh_term>
	<criteria>Biopsyproven Kaposi 's sarcoma least 14 cutaneous lesion , 12 measurable two dimension serve marker lesion ; 14 lesion must measure minimum 0.5 cm diameter , 4 mm punch biopsy entirely compose Kaposi 's sarcoma Serologic documentation HIV infection Food Drug Administration ( FDA ) approve test Karnofsky performance status &gt; = 60 % Hemoglobin &gt; = 8 g/dl Absolute neutrophil count &gt; = 750 cells/mm^3 Platelet count &gt; = 75,000/mm^3 Creatinine &lt; 1.5 time upper limit normal creatinine clearance &gt; = 60 mL/min Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) ; , however , elevate bilirubin felt secondary indinavir therapy , patient allow enroll protocol total bilirubin = &lt; 3.5 mg/dl provide direct bilirubin normal Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 3 x upper limit normal Life expectancy &gt; = 3 month Ability willingness give informed consent ; patient young 18 year age require consent parent guardian . All woman childbearing potential must negative serum b human chorionic gonadotropin ( HCG ) within 72 hour prior study entry must practice adequate birth control prevent pregnancy receive treatment three month treatment discontinue Patients must , opinion investigator , capable comply protocol Patients receive antiretroviral therapy must stable regimen least 12 week prior study entry without show evidence ongoing Kaposi 's sarcoma ( KS ) regression ( ie , less 25 % decrease size , number nodularity KS lesion opinion investigator ) ; patient may receive FDA approve antiretroviral therapy agent available treatment IND ; concurrent treatment highly active antiretroviral therapy strongly encourage , accordance DHHS guideline ( http : //www.aidsed.org/pdfs/adult_2402.pdf ) require participation Concurrent , acute , active , untreated opportunistic infection oral thrush genital herpes within 14 day enrollment Known active visceral Kaposi 's sarcoma symptomatic Kaposi 's sarcomarelated edema interferes function require cytotoxic therapy Concurrent neoplasia require cytotoxic therapy Acute treatment infection ( oral thrush genital herpes ) serious medical illness within 14 day study entry Antineoplastic treatment Kaposi 's sarcoma ( include chemotherapy , radiation therapy , local therapy , biological therapy , investigational therapy ) within four week study entry Previous local therapy KSindicator lesion within 60 day unless lesion clearly progress since treatment Corticosteroid treatment , replacement dos Use investigational agent antiretroviral drug available expand access compassionate use protocols Pregnant breast feeding female exclude participation study since effect halofuginone unborn young child unknown may potentially toxic</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>